Biomarkers in cancer micrometastasis: Where are we at?

Bioanalysis

Volumn 2, Issue 5, 2010, Pages 881-899

  Gerges, Noha ^a   Jabado, Nada ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA THROMBOGLOBULIN; BIOLOGICAL MARKER; CELL DNA; KI 67 ANTIGEN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; NESTIN; PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; VASCULOTROPIN RECEPTOR; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CHROMATIN IMMUNOPRECIPITATION; COMPARTMENT MODEL; ENDOTHELIAL PROGENITOR CELL; ENRICHMENT CULTURE; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENETIC PREDISPOSITION; HORIZONTAL GENE TRANSFER; HUMAN; IMMUNOCYTOCHEMISTRY; LASER SCANNING CYTOMETRY; METASTASIS; METASTASIS POTENTIAL; MICROFLUIDIC ANALYSIS; MOLECULAR PATHOLOGY; NONHUMAN; NUCLEIC ACID ANALYSIS; ONCOGENE; PROTEIN EXPRESSION; REVIEW; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR SEEDING; TUMOR VOLUME; ANIMAL; BIOLOGICAL MODEL; BLOOD; BLOOD CLOTTING; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; BLOOD COAGULATION; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79952530893     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.49     Document Type: Review

References (105)

1. Weiss L. Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev. 19(3-4), I-XI, 193-383 (2000).
2. Jacob K, Sollier C, Jabado N. Circulating tumor cells: detection, molecular profiling and future prospects. Expert Rev. Proteomics 4(6), 741-756 (2007). (Pubitemid 350261440)
3. Fidler IJ. Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother. Pharmacol. 43(Suppl.), S3-10 (1999). (Pubitemid 29244626)
4. Coman DR, de Long RP, McCutcheon M. Studies on the mechanisms of metastasis; the distribution of tumors in various organs in relation to the distribution of arterial emboli. Cancer Res. 11(8), 648-651 (1951).
5. Mocellin S, Keilholz U, Rossi CR, Nitti D. Circulating tumor cells: the 'leukemic phase' of solid cancers. Trends Mol. Med. 12(3), 130-139 (2006).
6. Al-Nedawi K, Meehan B, Rak J. Microvesicles: messengers and mediators of tumor progression. Cell Cycle 8(13), 2014-2018 (2009).
7. Al-Nedawi K, Meehan B, Micallef J et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 10(5), 619-624 (2008). (Pubitemid 351627382)
8. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1, 571-573 (1889).
9. Fidler IJ. Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg. Oncol. Clin. N. Am. 10(2), 257-269, VII-VIIII (2001). (Pubitemid 32472529)
10. Whiteside TL, Herberman RB. The role of natural killer cells in immune surveillance of cancer. Curr. Opin. Immunol. 7(5), 704-710 (1995).
11. Klement H, St Croix B, Milsom C et al. Atherosclerosis and vascular aging as modifiers of tumor progression, angiogenesis, and responsiveness to therapy. Am. J. Pathol. 171(4), 1342-1351 (2007). (Pubitemid 47582907)
12. Nanda A, Karim B, Peng Z et al. Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proc. Natl Acad. Sci. USA 103(9), 3351-3356 (2006). (Pubitemid 43346473)
13. Rak JW, St Croix BD, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 6(1), 3-18 (1995).
14. Seaman S, Stevens J, Yang MY et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11(6), 539-554 (2007). (Pubitemid 46856908)
15. St Croix B, Sheehan C, Rak JW et al. E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1).J. Cell Biol. 142(2), 557-571 (1998). (Pubitemid 28361560)
16. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6(4), 273-286 (2007). (Pubitemid 46505878)
17. Hart IR, Fidler IJ. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res. 40(7), 2281-2287 (1980). (Pubitemid 10082239)
18. Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res. 66(23), 11089-11093 (2006).
19. Arteaga CL, Baselga J. Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell 5(6), 525-531 (2004). (Pubitemid 38748914)
20. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005). (Pubitemid 41464706)
21. Weinstein IB, Joe AK. Mechanisms of disease: oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 3(8), 448-457 (2006). (Pubitemid 44203817)
22. Singletary SE, Greene FL, Sobin LH. Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. Cancer 98(12), 2740-2741 (2003). (Pubitemid 37509544)
23. Singletary SE, Greene FL. Revision of breast cancer staging: the 6th edition of the TNM classification. Semin. Surg. Oncol. 21(1), 53-59 (2003). (Pubitemid 37127474)
24. Hermanek P, Sobin LH, Wittekind C. How to improve the present TNM staging system. Cancer 86(11), 2189-2191 (1999). (Pubitemid 30010354)
25. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25(33), 5287-5312 (2007). (Pubitemid 350232263)
26. Fidler IJ. Angiogenesis and cancer metastasis. Cancer J. 6(Suppl. 2), S134-S141 (2000). (Pubitemid 30469150)
27. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3(6), 453-458 (2003). (Pubitemid 37328849)
28. Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 3(1), 53-57 (2002). (Pubitemid 34121146)
29. Chambers AF, Naumov GN, Vantyghem SA, Tuck AB. Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Res. 2(6), 400-407 (2000). (Pubitemid 32223636)
30. Cameron MD, Schmidt EE, Kerkvliet N et al. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res. 60(9), 2541-2546 (2000). (Pubitemid 30262450)
31. Naumov GN, MacDonald IC, Weinmeister PM et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res. 62(7), 2162-2168 (2002). (Pubitemid 34408466)
32. Wong CW, Lee A, Shientag L et al. Apoptosis: an early event in metastatic inefficiency. Cancer Res. 61(1), 333-338 (2001). (Pubitemid 32095735)
33. Nowell PC. The clonal evolution of tumor cell populations. Science 194(4260), 23-28 (1976).
34. Klein CA. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 9(4), 302-312 (2009).
35. Hunter KW, Crawford NP, Alsarraj J. Mechanisms of metastasis. Breast Cancer Res. 10(Suppl. 1), S2 (2008).
36. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61(5), 759-767 (1990).
37. Klein CA, Blankenstein TJ, Schmidt-Kittler O et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360(9334), 683-689 (2002). (Pubitemid 35232337)
38. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 197(4306), 893-895 (1977). (Pubitemid 8168759)
39. Khalique L, Ayhan A, Whittaker JC et al. The clonal evolution of metastases from primary serous epithelial ovarian cancers. Int. J. Cancer 124(7), 1579-1586 (2009).
40. Collins VP, Loeffler RK, Tivey H. Observations on growth rates of human tumors. Am. J. Roentgenol. Radium Ther. Nucl. Med. 76(5), 988-1000 (1956).
41. Greene FL, Sobin LH. The staging of cancer: a retrospective and prospective appraisal. CA Cancer J. Clin. 58(3), 180-190 (2008). (Pubitemid 351830301)
42. Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin. Exp. Metastasis 26(1), 19-34 (2009).
43. Abbruzzese JL, Abbruzzese MC, Hess KR et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J. Clin. Oncol. 12(6), 1272-1280 (1994). (Pubitemid 24173944)
44. Pawelek JM, Chakraborty AK. The cancer cell - leukocyte fusion theory of metastasis. Adv. Cancer Res. 101, 397-444 (2008).
45. Martin TA, Goyal A, Watkins G, Jiang WG. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann. Surg. Oncol. 12(6), 488-496 (2005). (Pubitemid 40884264)
46. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37(3), 646-650 (1977). (Pubitemid 8051621)
47. Bendich A, Wilczok T, Borenfreund E. Circulating DNA as a possible factor in oncogenesis. Science 148, 374-376 (1965).
48. Garcia-Olmo D, Garcia-Olmo DC. Functionality of circulating DNA: the hypothesis of genometastasis. Ann. NY Acad. Sci. 945, 265-275 (2001). (Pubitemid 33022463)
49. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell Biol. 12(3), 954-961 (1992).
50. Biernat W, Huang H, Yokoo H, Kleihues P, Ohgaki H. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol. 14(2), 131-136 (2004). (Pubitemid 38656384)
51. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33(1), 49-54 (2003). (Pubitemid 36068681)
52. Bild AH, Yao G, Chang JT et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439(7074), 353-357 (2006). (Pubitemid 43128862)
53. Lee AV, Chamness G, Oesterreich S. 26th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 3-6 December 2003: update on preclinical and translational research. Breast Cancer Res. 6(2), E10 (2004).
54. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001). (Pubitemid 32878711)
55. Lifsted T, Le Voyer T, Williams M et al. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int. J. Cancer 77(4), 640-644 (1998). (Pubitemid 28340915)
56. Park YG, Zhao X, Lesueur F et al. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat. Genet. 37(10), 1055-1062 (2005). (Pubitemid 41486657)
57. Cao Z, Song JH, Park YK et al. The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. Neoplasma 56(2), 114-118 (2009).
58. Yang H, Crawford N, Lukes L et al. Metastasis predictive signature profiles pre-exist in normal tissues. Clin. Exp. Metastasis 22(7), 593-603 (2005). (Pubitemid 43234644)
59. Kim MY, Oskarsson T, Acharyya S et al. Tumor self-seeding by circulating cancer cells. Cell 139(7), 1315-1326 (2009).
60. Niers TM, Klerk CP, DiNisio M et al. Mechanisms of heparin induced anticancer activity in experimental cancer models. Crit. Rev. Oncol. Hematol. 61(3), 195-207 (2007). (Pubitemid 46329424)
61. Koch M, Kienle P, Hinz U et al. Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases. Ann. Surg. 241(2), 199-205 (2005).
62. Slade MJ, Coombes RC. The clinical significance of disseminated tumor cells in breast cancer. Nat. Clin. Pract. Oncol. 4(1), 30-41 (2007). (Pubitemid 46017692)
63. Pierga JY, Bonneton C, Vincent-Salomon A et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin. Cancer Res. 10(4), 1392-1400 (2004). (Pubitemid 38365234)
64. Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin. Oncol. 33(3 Suppl. 9), S9-S14 (2006).
65. Ignatiadis M, Xenidis N, Perraki M et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J. Clin. Oncol. 25(33), 5194-5202 (2007). (Pubitemid 350232250)
66. Ignatiadis M, Perraki M, Apostolaki S et al. Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer. Clin. Breast Cancer 7(11), 883-889 (2007).
67. Braun S, Pantel K, Muller P et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med. 342(8), 525-533 (2000). (Pubitemid 30117892)
68. Schmidt H, DeAngelis G, Eltze E et al. Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene. Cancer Res. 66(18), 8959-8965 (2006). (Pubitemid 44521111)
69. Solakoglu O, Maierhofer C, Lahr G et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc. Natl Acad. Sci. USA 99(4), 2246-2251 (2002). (Pubitemid 34169046)
70. Braun S, Vogl FD, Naume B et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353(8), 793-802 (2005). (Pubitemid 41215488)
71. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 253(2), 180-204 (2007). (Pubitemid 47017533)
72. Mostert B, Sleijfer S, Foekens JA, Gratama JW. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat. Rev. 35(5), 463-474 (2009).
73. Vona G, Sabile A, Louha M et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am. J. Pathol. 156(1), 57-63 (2000). (Pubitemid 30644439)
74. Naume B, Borgen E, Tossvik S et al. Detection of isolated tumor cells in peripheral blood and in BM: evaluation of a new enrichment method. Cytotherapy 6(3), 244-252 (2004). (Pubitemid 38868097)
75. Krivacic RT, Ladanyi A, Curry DN et al. A rare-cell detector for cancer. Proc. Natl Acad. Sci. USA 101(29), 10501-10504 (2004). (Pubitemid 38955770)
76. He W, Wang H, Hartmann LC, Cheng JX, Low PS. In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. Proc. Natl Acad. Sci. USA 104(28), 11760-11765 (2007). (Pubitemid 47175086)
77. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer 6(11), 835-845 (2006). (Pubitemid 44629895)
78. Gerhard M, Juhl H, Kalthoff H et al. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J. Clin. Oncol. 12(4), 725-729 (1994). (Pubitemid 24110911)
79. Ghossein RA, Scher HI, Gerald WL et al. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J. Clin. Oncol. 13(5), 1195-1200 (1995).
80. Kaplan JC, Kahn A, Chelly J. Illegitimate transcription: its use in the study of inherited disease. Hum. Mutat. 1(5), 357-360 (1992).
81. Schoenfeld A, Luqmani Y, Smith D et al. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res. 54(11), 2986-2990 (1994). (Pubitemid 24187784)
82. Johnson PW, Burchill SA, Selby PJ. The molecular detection of circulating tumour cells. Br. J. Cancer 72(2), 268-276 (1995).
83. Ghossein RA, Bhattacharya S, Rosai J. Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin. Cancer Res. 5(8), 1950-1960 (1999). (Pubitemid 29399243)
84. Ghossein RA, Carusone L, Bhattacharya S. Review: polymerase chain reaction detection of micrometastases and circulating tumor cells: application to melanoma, prostate, and thyroid carcinomas. Diagn. Mol. Pathol. 8(4), 165-175 (1999). (Pubitemid 30003330)
85. Ghossein RA, Osman I, Bhattacharya S et al. Detection of prostatic specific membrane antigen messenger RNA using immunobead reverse transcriptase polymerase chain reaction. Diagn. Mol. Pathol. 8(2), 59-65 (1999). (Pubitemid 29399034)
86. Zieglschmid V, Hollmann C, Gutierrez B et al. Combination of immunomagnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells. Anticancer Res. 25(3A), 1803-1810 (2005). (Pubitemid 40896806)
87. Riethdorf S, Fritsche H, Muller V et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin. Cancer Res. 13(3), 920-928 (2007). (Pubitemid 46340368)
88. Pierga JY, Bidard FC, Mathiot C et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a Phase II randomized trial. Clin. Cancer Res. 14(21), 7004-7010 (2008).
89. Bidard FC, Saliba AE, Saias L et al. [Circulating tumor cells and breast cancer: detection techniques and clinical results]. Bull. Cancer 96(1), 73-86 (2009).
90. Nagrath S, Sequist LV, Maheswaran S et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450(7173), 1235-1239 (2007).
91. Alix-Panabieres C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin. Cancer Res. 14(16), 5013-5021 (2008).
92. Kojima T, Hashimoto Y, Watanabe Y et al. A simple biological imaging system for detecting viable human circulating tumor cells. J. Clin Invest. 119(10), 3172-3181 (2009).
93. Schwarzenbach H, Muller V, Stahmann N, Pantel K. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer. Ann. NY Acad. Sci. 1022, 25-32 (2004). (Pubitemid 38951577)
94. Schwarzenbach H, Chun FK, Lange I et al. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. Int. J. Cancer 120(7), 1465-1471 (2007). (Pubitemid 46355381)
95. Schwarzenbach H, Alix-Panabieres C, Muller I et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin. Cancer Res. 15(3), 1032-1038 (2009).
96. Martin KJ, Graner E, Li Y et al. High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood. Proc. Natl Acad. Sci. USA 98(5), 2646-2651 (2001). (Pubitemid 32209536)
97. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 435(7043), 834-838 (2005). (Pubitemid 40839735)
98. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105(30), 10513-10518 (2008).
99. Yee J, Sadar MD, Sin DD et al. Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J. Clin. Oncol. 27(17), 2787-2792 (2009).
100. Kato H, Semba S, Miskad UA et al. High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases. Clin. Cancer Res. 10(21), 7318-7328 (2004). (Pubitemid 39487721)
101. Bessette DC, Qiu D, Pallen CJ. PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev. 27(2), 231-252 (2008).
102. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Res. 69(11), 4708-4715 (2009).
103. Calleri A, Bono A, Bagnardi V et al. Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin. Cancer Res. 15(24), 7652-7657 (2009).
104. Skog J, Wurdinger T, van Rijn S et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10(12), 1470-1476 (2008).
105. Hong BS, Cho JH, Kim H et al. Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics 10, 556 (2009).